# Exelixis, Inc.  Share Price Target ‘$36.89’, now 7.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/exelixis-inc-share-price-target-36-89-now-7-9-upside-potential/4121187033
- Published: 2025-02-20T16:28:59+00:00
- Author: Charlotte Edwards

**Exelixis, Inc.** with ticker code (EXEL) have now 23 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The target price High/
Low ranges between $45.00 and $23.00 calculating the average target share price 
we see $36.89. (at the time of writing). Given that the stocks previous close was
at $34.20 this would indicate that there is a potential upside of 7.9%. There is
a 50 day moving average of $34.26 while the 200 day moving average is $28.11. The
total market capitalization for the company now stands at 9.82B. The current share
price for the company is: $35.07 USD

 The potential market cap would be $10,586,086,233 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 19.93, revenue per share of $7.48
and a 14.64% return on assets.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines
and combination regimens at the forefront of cancer care. It has four products, 
including its flagship molecule, cabozantinib, which is an inhibitor of multiple
tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved
as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and
in combination with Bristol-Myers Squibb Company’s (BMS) OPDIVO (nivolumab), for
hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated
thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic
medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor
of MEK approved as part of multiple combination regimens to treat specific forms
of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR) approved the treatment of hypertension.

Share on:
